High percentage of evanescent red cell antibodies in patients with sickle cell disease highlights need for a national antibody database

Academic Article

Abstract

  • © 2016 by The Southern Medical Association. Objectives Alloantibody formation secondary to transfusion in patients with sickle cell disease (SCD) is a well-known phenomenon. Pretransfusion testing (eg, "antibody screening") protects patients from receiving incompatible red blood cell transfusions. Because alloantibodies have a tendency to evanesce (ie, become undetectable over time), however, this phenomenon puts patients at risk of a delayed hemolytic transfusion reaction or even acute hemolysis. Methods We evaluated the records of 71 patients with SCD with alloantibodies detected during a 2-year period to describe their most common specificities and their rate of evanescence. Results We found that 81% of patients had at least one antibody that was undetectable during the study period; therefore, if patients were transfused with antigen-positive units at a facility that was unaware of their antibody history, life-threatening hemolysis could develop. Conclusions Evanescence is a real risk for patients with SCD, and national/regional databases of alloantibodies should be considered a priority.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Williams LA; Lorenz RG; Tahir A; Pham HP; Marques MB
  • Start Page

  • 588
  • End Page

  • 591
  • Volume

  • 109
  • Issue

  • 9